Literature DB >> 27364517

Impact of Formulation on the Pharmacokinetic Profile of Dutasteride.

Martin C Michel1.   

Abstract

Entities:  

Year:  2016        PMID： 27364517     DOI： 10.1007/s40261-016-0429-4

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  11 in total

1.  Impact of Formulation on the Pharmacokinetics of Dutasteride: Results from Two Phase I Studies.

Authors:  Michael Fossler; John Zhu; Claus Roehrborn; Paul McAleese; Michael Manyak
Journal:  Clin Drug Investig       Date:  2016-09       Impact factor: 2.859

2.  Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.

Authors:  Claus G Roehrborn; Igor Oyarzabal Perez; Erik P M Roos; Nicolae Calomfirescu; Betsy Brotherton; Fang Wang; Juan Manuel Palacios; Averyan Vasylyev; Michael J Manyak
Journal:  BJU Int       Date:  2015-01-29       Impact factor: 5.588

3.  Pharmacokinetic bioequivalence studies of a fixed-dose combination of tamsulosin and dutasteride in healthy volunteers.

Authors:  Michael J Fossler; David A Collins; Meg M Thompson; Antonio Nino; Joseph J Bianco; Dushen Chetty
Journal:  Clin Drug Investig       Date:  2014-05       Impact factor: 2.859

4.  Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.

Authors:  F M Debruyne; A Jardin; D Colloi; L Resel; W P Witjes; M C Delauche-Cavallier; C McCarthy; C Geffriaud-Ricouard
Journal:  Eur Urol       Date:  1998-09       Impact factor: 20.096

5.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

Authors:  John D McConnell; Claus G Roehrborn; Oliver M Bautista; Gerald L Andriole; Christopher M Dixon; John W Kusek; Herbert Lepor; Kevin T McVary; Leroy M Nyberg; Harry S Clarke; E David Crawford; Ananias Diokno; John P Foley; Harris E Foster; Stephen C Jacobs; Steven A Kaplan; Karl J Kreder; Michael M Lieber; M Scott Lucia; Gary J Miller; Mani Menon; Douglas F Milam; Joe W Ramsdell; Noah S Schenkman; Kevin M Slawin; Joseph A Smith
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

Review 6.  Dutasteride.

Authors:  Hannah C Evans; Karen L Goa
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial.

Authors:  Roger S Kirby; Claus Roehrborn; Peter Boyle; Georg Bartsch; Alain Jardin; Margaret M Cary; Michael Sweeney; Eric B Grossman
Journal:  Urology       Date:  2003-01       Impact factor: 2.649

8.  The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.

Authors:  Claus G Roehrborn; Paul Siami; Jack Barkin; Ronaldo Damião; Kim Major-Walker; Indrani Nandy; Betsy B Morrill; R Paul Gagnier; Francesco Montorsi
Journal:  Eur Urol       Date:  2009-09-19       Impact factor: 20.096

9.  The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.

Authors:  H Lepor; W O Williford; M J Barry; M K Brawer; C M Dixon; G Gormley; C Haakenson; M Machi; P Narayan; R J Padley
Journal:  N Engl J Med       Date:  1996-08-22       Impact factor: 91.245

10.  Glibenclamide transdermal patches: physicochemical, pharmacodynamic, and pharmacokinetic evaluations.

Authors:  S Mutalik; N Udupa
Journal:  J Pharm Sci       Date:  2004-06       Impact factor: 3.534
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.